Esomeprazole (Nexium) - Uses, Method of Action, Dosage and side effectsEsomeprazole is a proton pump inhibitor developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. It is available under brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium and South Africa. Generic Nexium in Tablet form is also now available. Method Of ActionEsomeprazole is a proton pump inhibitor which reduces gastric acid secretion through inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents formation of gastric acid. Esomeprazole DosageEsomeprazole is available as delayed-release capsules in the United States. In Australia and Canada as well as several other countries it is available as delayed release tablets in containing esomeprazole magnesium in strengths of 20 mg and 40 mg. It is also available as esomeprazole sodium for intravenous injection/infusion. Side Effects Of EsomeprazoleCommon side effects include headache, diarrhea, nausea, gas, decreased appetite, constipation, dry mouth, and abdominal pain. More severe side effects are severe allergic reactions, chest pain, dark urine, fast heartbeat, fever, persistent sore throat, severe stomach pain, unusual bruising or bleeding, unusual tiredness, and yellowing of the eyes or skin. Interactions with Other DrugsEsomeprazole is a competitive inhibitor of the enzymes CYP2C19 and CYP2C9, and may therefore interact with drugs that depend on them for metabolism, such as diazepam and warfarin; the concentrations of these drugs may increase if they are used concomitantly with esomeprazole. Conversely, Clopidogrel (Plavix) is an inactive prodrug that partially depends on CYP2C19 for conversion to its active form; inhibition of CYP2C19 blocks the activation of clopidogrel, thus reducing its effects. Further InformationManufacturers pamphlet: Astra Zeneca's Nexium Information
|
| Last Updated on Tuesday, 06 April 2010 10:43 |